Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mucinex Ads Cast Consumers As Heroes Fighting ‘Mr. Mucus’

This article was originally published in The Tan Sheet

Executive Summary

RB revamps advertising for Mucinex for the first time in 10 years to encourage consumers to kick butt during the cold and flu season. The new campaign still includes the green ne'er-do-well “Mr. Mucus,” but gives him a slightly gentler personality and a three-dimensional body.

You may also be interested in...



Reckitt Extends Mucinex, Airborne Lines In Global Consumer Expansion

The U.K. firm extends Mucinex outside the decongestant category to treating allergies, where the brand faces strong branded and private label competition. An Airborne supplement line extension and wider distribution of MegaRed omega-3 products also factor in the firm’s 2014 consumer health care plans.

J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores

J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.

Ensuring Leading Position For GSK Consumer Products Touted In Management Shift

GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS107225

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel